


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula



including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein

X is N or CH;

R¹ is C₁₋₆alkyl, NR⁶R⁷, OR⁷ or SR⁷;

in case X is N then R² is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or C₁₋₆alkylthio;

in case X is CH then R² is C₁₋₆alkyl, C₁₋₆alkyloxy or C₁₋₆alkylthio;

R³ is Ar¹ or Het¹;

R⁴ and R⁵ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C₁₋₆alkyl)amino;

R⁶ is hydrogen, C₁₋₈alkyl, mono- or di(C₃₋₆cycloalkyl)methyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyloxyC₁₋₆alkyl or C₁₋₆alkyloxyC₁₋₆alkyl;

R⁷ is C₁₋₈alkyl, mono- or di(C₃₋₆cycloalkyl)methyl, Ar²CH², C₁₋₆alkyloxy-C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₃₋₆alkenyl, thienylmethyl, furanylmethyl, C₁₋₆alkylthioC₁₋₆alkyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, di(C₁₋₆alkyl)amino, C₁₋₆alkylcarbonylC₁₋₆alkyl;

or R⁶ and R⁷ taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C₁₋₆alkyl or C₁₋₆alkyloxyC₁₋₆alkyl; and

Ar¹ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁₋₆alkyl, trifluoromethyl, hydroxy, cyano, C₁₋₆alkyloxy, benzyloxy, C₁₋₆alkylthio, nitro, amino and mono- or di(C₁₋₆alkyl)amino;

Het¹ is pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁₋₆alkyl, trifluoromethyl, hydroxy, cyano, C₁₋₆alkyloxy, benzyloxy, C₁₋₆alkylthio, nitro, amino, and mono- or di(C₁₋₆alkyl)amino; and

Ar² is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, di(C₁₋₆alkyl)aminoC₁₋₆alkyl, trifluoromethyl;

with the proviso that 2,4-dimethyl-8-(2-nitrophenyl)-quinoline is not included.

2. (Currently Amended) A compound according to claim 1 wherein R¹ is OR⁷ or SR⁷ and R⁷ is C₁₋₆alkyl; or R¹ is NR⁶R⁷ and R⁶ is hydrogen or C₁₋₆alkyl, and R⁷ is C₁₋₆alkyl or C₃₋₆cycloalkylmethyl; R² is C₁₋₆alkyl; R³ is a phenyl substituted with 1, 2 or 3 substituents each independently selected from C₁₋₆alkyl, C₁₋₆alkyloxy or halo, or R³ is a pyridinyl substituted with 1, 2 or 3 substituents each independently selected from C₁₋₆alkyl or di(C₁₋₆alkyl)amino; and R⁴ or and R⁵ are each independently selected from hydrogen or C₁₋₆alkyl.

3. (Previously Presented) A compound according to claim 1 wherein R¹ is NR⁶R⁷ wherein R⁶ is C₂₋₄alkyl and R⁷ is C₂₋₄alkyl or cyclopropylmethyl; R² is C₁₋₂alkyl; R³ is phenyl substituted with 1, 2 or 3 substituents each independently selected from hydrogen, halo or C₁₋₆alkyl.

4. (Previously Presented) A compound according to claim 1 wherein R¹ is NR⁶R⁷ wherein R⁶ is C₃₋₄alkyl and R⁷ is C₃₋₄alkyl or cyclopropylmethyl; R² is methyl; R³ is 3-pyridinyl substituted on the 4- and/or 6-position with methyl or dimethylamino.

5. (Canceled)

6. (Previously Presented) A composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1.

7. (Previously Presented) A process for preparing a composition as claimed in claim 6 wherein a therapeutically effective amount of a compound as claimed in claim 1 is intimately mixed with a pharmaceutically acceptable carrier.

8.-12. (Canceled)

13. (Previously Presented) A method of antagonizing a CRF receptor in a warm-blooded animal, comprising administering to the animal an effective amount of a compound of claim 1.

14. (Previously Presented) A method of treating a disorder manifesting hypersecretion of CRF in a warm-blooded animal, comprising administering to the animal an effective amount of a compound of claim 1.

15. (Currently Amended) The method of claim 14 wherein the disorder is selected from depression, an anxiety-related disorder, a feeding disorder, stress-induced immune suppression, stroke, Cushing's disease, infantile spasms, epilepsy, seizure, and an inflammatory condition.

16. (Original) The method of claim 15 wherein the feeding disorder is anorexia nervosa, bulimia or irritable bowel syndrome.